Floatz logo

Brentuximab Vedotin

NK-Cell Lymphoma

New York Medical Collegeantibody_drug_conjugateEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the NK-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
New York Medical College
Phase 3BBB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 3BB
CYCLOSPORIN A
Medical College of Wisconsin
Phase 3B
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2B
Equine Atg
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 26 →

Same molecule, other indications

Brentuximab Vedotin is also rated in:

T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
anaplastic large cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →